Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors
-
RESULT OF RIKSBANK CERTIFICATE SALE
-
Novarra BBX Expands Tokenization Infrastructure Platform to Meet Growing Institutional Demand for Real-World Asset Markets
-
Nature Translational Psychiatry Study Reveals Distinct Functional Neuronal Signatures in Patient-Derived Brain Organoids with Itay&Beyond’s Neurotech Platform
-
Scandinavian Tobacco Group A/S. Notice convening the Annual General Meeting
-
Transactions in connection with share buy-back program
-
Titanbay Appoints Julius Kolberg as Head of Germany
-
Nature Translational Psychiatry Study Reveals Distinct Functional Neuronal Signatures in Patient-Derived Brain Organoids with Itay&Beyond’s Neurotech Platform
-
Form 8.3 - [IDOX PLC - 23 03 2026] - (CGWL)
-
DeepBrain AI Launches Interactive AI Video Agents for Enterprise
-
Hesai Group Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results
-
Smithfield Foods Reports Record Fiscal 2025 Results
-
Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant
-
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
-
ONERugged Vehicle-Mounted Computer V82T Launches to Transform Fleet Management
-
Connecting the World, Driving Apex Growth: Apexmind Summit 2026 Successfully Held in HongKong
-
Kandi Technologies Unveils Brand Upgrade to Highlight Intelligent Transformation and Diversified Growth Strategy
-
Netflix’s Chief Marketing Officer, Marian Lee, Takes Center Stage at Licensing Expo 2026 for an Opening Keynote on the Netflix Effect and Fandom
-
TRESU Investment Holding A/S – Settlement of interest payment by issuance of interest bonds
-
Aspo’s Annual Review 2025 has been published
-
Micro, AMFI and CEiiA Join Forces to create the next generation microcars and industrialize BEN in Turin
-
The notes redeemed by Municipality Finance have been removed from trading at Nasdaq Helsinki
-
Municipality Finance issues a GBP 70 million tap under its MTN programme
-
Henley Opportunity Index 2026: The Citizenship and Residence Options That Unlock the World’s Greatest Opportunities
-
Succession at Jyske Realkredit A/S
-
Debt-Free Acquisition. Increase in Free Float.
-
ALSTOM S.A: Alstom will upgrade the Skyway at Houston Intercontinental Airport and continue operations and maintenance for 15 years
-
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
-
JELENEW Opens New Store in Barcelona, Joining the Spanish Women’s Cycling Journey
-
Mission Trail Capital Takes 5% Stake in Sidetrade, Second US Investor to Build Significant Position in Under Three Months
-
SUSE Advances Intelligent Infrastructure Management with Latest AI and Virtualization Updates
-
NBPE Announces Transaction in Own Shares
-
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
-
Net Asset Value and Dividend Declaration
-
TRANSFER OF HARVIA’S OWN SHARES AS REWARDS UNDER INCENTIVE PROGRAM
-
Equinor ASA: Share buy-back – first tranche for 2026
-
Progress on share buyback programme
-
Elis: Disclosure of trading in own shares occured from March 16 to March 20, 2026
-
SBM Offshore awarded FEED contracts for the Longtail project in Guyana
-
Transaction in Own Shares
-
Technip Energies convenes its 2026 Annual General Meeting
-
Press release: Availability of the Q1 2026 aide-mémoire
-
CGTN: How Xiongan is evolving into a model for high-quality urban growth
-
Biotalys Announces New Dates for the Publication of its 2025 Annual Report and for its Annual Shareholders Meeting
-
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
-
Start of Day Message
-
Idorsia announces the nomination of three candidates for election to the Board of Directors
-
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
-
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
-
ABC arbitrage: 2025 Results

